(SESN) – FDA
-
FDA Approves First Gene Therapy for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer
-
Sesen Bio (SESN) to Pause Clinical Development of Vicineum in the US
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SESN Stock Lookup